Apnimed, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Apnimed, Inc. (APMD) reported Net Income (Loss) Available to Common Stockholders, Diluted of $126.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-08.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-09-08
- Apnimed, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $126.73M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month |
|---|---|---|
| 2026-06-30 | $126.73M 10-Q · filed 2026-09-08 | $192.34M 10-Q · filed 2026-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B |